ASCO joined nearly 270 patient and provider advocacy groups in signing a letter (LINK) to U.S. Department of Health and Human Services (HHS) Secretary Tom Price, urging the agency to formally withdraw the Obama Administration’s proposed Medicare Part B Drug Payment Model.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The next installment of ASCO’s webinar series on the Quality Payment Program (QPP) will take place Monday, June 19 at 4:00 p.m. ET. The webinar, entitled Quality Payment Program: Scoring for Advancing Care Information and Improvement Activities, will help participants understand QPP’s Advancing Care Information and Improvement Activities Attestation measures. These measures make up two of the four categories that determine a Merit-Based Incentive Payment System (MIPS) score, and ultimately participants’ Medicare Part B reimbursement.
In a letter of intent (LOI) to the Physician-Focused Payment Model Technical Advisory Committee (PTAC), an advisory group to the Centers for Medicare & Medicaid Services (CMS), ASCO expressed its intent to submit a physician payment reform model for PTAC review and eventual consideration by CMS as an advanced alternative payment model (APM) under the Medicare Access and CHIP Reauthorization Act (MACRA) and the Quality Payment Program (QPP).
ASCO recently joined more than 180 patient and provider advocacy groups in signing a letter to the Medicare Payment Advisory Commission (MedPAC), urging the congressional advisory group to reconsider proposed changes to Medicare Part B drug reimbursement.
The Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act, launched in January 2017 and is being implemented in oncology practices across the country. 2017 is a transition year, but practices still have to report some quality data in order to avoid financial penalties in 2019. This transition year offers practices an opportunity to test the QPP reporting system before 2018, when quality reporting will require a significantly heavier lift to avoid financial penalties in 2020. ASCO is releasing a series of webinars to guide oncology practices to successful quality reporting.
The U.S. cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to ASCO's fourth annual State of Cancer Care in America report released March 22, 2017.
The Centers for Medicare & Medicaid Services has extended the data submission deadline for the Electronic Health Record (EHR) reporting mechanism of the 2016 Quality Reporting Document Architecture (QRDA) for the Physician Quality Reporting System (PQRS) program. Individual eligible professionals (EPs), PQRS group practices, qualified clinical data registries (QCDRs), and qualified EHR data submission vendors (DSVs) now have until Friday, March 31 at 8:00 p.m. Eastern Time to submit 2016 EHR data via QRDA.
ASCO recently joined more than 100 medical specialty groups and state medical societies in signing an American Medical Association-led letter urging the Centers for Medicare & Medicaid Services (CMS) and Office of the National Coordinator for Health Information (ONC) to delay requiring 2015 Edition Certified Electronic Health Record Technology (CEHRT) until such technology is widely available—and no sooner than January 2019.
The deadline to submit reconsideration applications for the 2017 Electronic Health Record (EHR) Incentive Program payment adjustment—based on the 2015 reporting period—is Feb. 28, 2017. Applications will not be accepted after the deadline.
ASCO’s "Criteria for High-Quality Clinical Pathways in Oncology," is now featured as a special article in the Journal of Oncology Practice. ASCO developed the 15 inter-related criteria to provide an overarching framework for assessing pathway programs in the United States and to guide stakeholders in assessing the quality, utility and integrity of clinical pathways in oncology.
An American Medical Association (AMA)-led coalition including ASCO and 15 other health care organizations today urged health plans, benefit managers, and other stakeholders to reform utilization management policies, including prior authorization requirements, imposed on medical tests, procedures, devices, and drugs.